How Fast Does Non-Small Cell Lung Cancer Grow?

early stages of lung cancer :: Article Creator

How Robotic Technology Is Being Used In Lung Cancer Diagnosis

Prev Next

We have a health alert we want to bring you. We've done several reports about the dangers of lung cancer – which is the deadliest form of cancer in the United States. I spoke with a lung cancer survivor and her doctor about the technology that saved her life. Plus, I talked to her doctor about what you can do to prevent this deadly disease. "I got sick over New Year's and went to the emergency room and was in the hospital for six days with pneumonia," said Debra Haberstroh. While in the hospital, Haberstroh would receive a diagnosis that would change her life. "They found a spot on my lungs. Actually, they found several, but most of them were resolved except one," Haberstroh explained.

TAMPA, Fla. — We have a health alert we want to bring you. We've done several reports about the dangers of lung cancer – which is the deadliest form of cancer in the United States.

I spoke with a lung cancer survivor and her doctor about the technology that saved her life. Plus, I talked to her doctor about what you can do to prevent this deadly disease.

"I got sick over New Year's and went to the emergency room and was in the hospital for six days with pneumonia," said Debra Haberstroh. While in the hospital, Haberstroh would receive a diagnosis that would change her life. "They found a spot on my lungs. Actually, they found several, but most of them were resolved except one," Haberstroh explained.

Her doctors told her it was lung cancer. "They did a bronchoscopy before I left the hospital," said Haberstroh.

The only problem was they couldn't reach the area where the cancer was located, and to add insult to injury, lung cancer patients only have a 17% survival rate.

"So, later, my pulmonologist called me, and she said that they had a new machine at Cleveland Clinic and they could do a robotic bronchoscopy, which is how I met Dr. Marsh," said Haberstroh.

Dr. Michael Marsh is a pulmonologist with the Cleveland Clinic Florida. "So, we were able to get to her very quickly and very safely obtain a biopsy. And after resection, Debra's cured," said Dr. Marsh.

Moffitt Cancer Center in Tampa also has this robotic technology.

How can you help prevent the onset of lung cancer?

Dr. Marsh: "Quit smoking, or not to start smoking, to begin with. Other things we can do is avoid second-hand smoke exposure, whether that's from those around us smoking cigarettes or other things. Staying away from chronic exposure to campfires. Anything that we shouldn't be inhaling."

Are smokers the only ones at risk of getting lung cancer?

Dr. Marsh: "Non-smokers are still at risk for developing lung cancer. Around 15% to 20% of lung cancers that we diagnose today are never smokers."

What are the symptoms of lung cancer?

Dr. Marsh: "That can be a little scary because, typically, especially in the early stages of lung cancer when it's most curable, we don't have any symptoms at all."

That's why pulmonologists recommend people between the ages of 50 and 80 who smoke or used to smoke get screened annually.

PrognomiQ's Latest Research Demonstrates The Potential Of Its Multi-omics Liquid Biopsy Platform In Early-Stage Detection Of Lung Cancer

– Multi-omics Blood-Based Biomarkers in Lung Cancer Reveal High Performance in Early Detection –

SAN MATEO, Calif., Jan. 8, 2024 /PRNewswire/ -- PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the early detection, treatment selection and recurrence monitoring of cancer and other complex diseases – today announced promising results from the largest, deep multi-omics study conducted to date. The study, published online in medRxiv, focused on subjects at risk for lung cancer, demonstrating the power of multi-omics to deliver both high sensitivity and high specificity in the detection of early-stage lung cancer.

PrognomiQ Logo (PRNewsfoto/PrognomiQ)

These encouraging data stem from a 2,513-subject case-control study which analyzed the molecular differences between the peripheral blood plasma of lung cancer subjects and non-cancer controls, many of whom were at high-risk for lung cancer. The study used a statistical classifier based on identified molecular features that demonstrated high performance in all stages of detection, including early-stage disease. Given the focus on high-risk populations in this study, the team focused on prioritizing high sensitivity, particularly for early-stage cancer. The research demonstrated:

89% overall sensitivity and 89% specificity in the validation cohort

80% sensitivity for stage I lung cancer

88% sensitivity for stage II lung cancer

98-100% sensitivity for stage III-IV lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide, with 238,340 new cases and 127,070 deaths estimated in the United States in 2023. The current standard of care, for the over 14 million high-risk individuals in the U.S. Eligible for lung cancer screening, is low-dose computed tomography (LDCT) scanning. Although these screening recommendations were originally made in 2013, LDCTs remain underutilized, with low adherence rates of less than 10% due to a number of factors at both the patient and provider level, including having a wide range in the reported sensitivity and specificity performance as well as high false-positivity of LDCT tests.

Story continues

"The unmet need for early detection through convenient and accessible modalities is exceptionally high, particularly for early-stage lung cancer that is both highly treatable and potentially curable," said Brian Koh, Chief Medical Officer of PrognomiQ. "These latest findings further validate the power of our platform to discover new biology and biomarkers and to transform the performance of liquid biopsy tests using a multi-omics approach. Given the current adoption challenges of LDCT scanning, a blood-based test to detect lung cancer with high sensitivity and specificity performance, particularly at the early stages, could dramatically improve lung cancer screening rates. We're truly excited about the opportunities to transform the detection and treatment of lung cancer."

These findings add to the body of research previously presented in 2023 on lung cancer detection at both the American College of Chest Physicians (CHEST) and the World Conference on Lung Cancer (WCLC), and on pancreatic cancer detection at the American Association of Cancer Research (AACR) annual conferences. PrognomiQ is currently enrolling a prospective 15,000 subject study in lung cancer initiated in 2023 to support registration. Additionally, the company was recently granted a Clinical Laboratory Improvement Amendment (CLIA) license, which will further enable development of an early detection test for lung cancer.

PrognomiQ's proprietary approach leverages cutting-edge technologies, including Seer's Proteograph™ Product Suite, which enables collection of deep, unbiased proteomics data. In addition to proteomics, PrognomiQ interrogates the range of data from genotype to phenotype including cell-free DNA, RNA, metabolites, and lipids to identify potential biomarkers of significance. The combination of proteomic data with genomic, metabolomic, epigenomic, and transcriptomic data provides unparalleled levels of novel biological insights which could lead to transformative new approaches to diagnostic and therapy development.

Seer CEO Omid Farokhazad will be highlighting PrognomiQ's multi-omics lung cancer study as part of Seer's presentation at the J.P. Morgan Healthcare Conference on Wednesday, January 10th at 3:00 p.M. (Pacific Time)/6:00 p.M. (Eastern Time).

About PrognomiQ:Founded in 2020, PrognomiQ is a healthcare company pursuing the development of multi-omics human tests for cancer and other complex diseases. PrognomiQ uses leading-edge proteomics technologies, in addition to metabolomics and genomics technologies, to develop multi-omics products to improve human health. For more information, please visit www.Prognomiq.Com.

Media ContactBetsy Levyblevy@greenroompr.Com 415-377-3112

Cision

View original content to download multimedia:https://www.Prnewswire.Com/news-releases/prognomiqs-latest-research-demonstrates-the-potential-of-its-multi-omics-liquid-biopsy-platform-in-early-stage-detection-of-lung-cancer-302027584.Html

SOURCE PrognomiQ

Kathy Brown Diagnosed With Stage Four Lung Cancer: Legendary House Singer, 63, Undergoes Surgery After Disease Spread To Her Brain - With Fundraiser Launched To Pay For Her ...

By Eve Buckland For Dailymail.Com

Published: 13:13 EST, 11 January 2024Updated: 14:09 EST, 11 January 2024

Legendary house music singer Kathy Brown has been diagnosed with stage four lung cancer - with the disease spreading to her brain.

Brown, 63, known for songs including Turn Me Out (Turn to Sugar) and Strings of Life (Stronger on My Own) was diagnosed late last year after being being admitted to ICU in her hometown of Charleston, South Carolina.

Doctors performed surgery to try and reduce swelling on Brown's brain - with the star currently undergoing a course of radiotherapy and immunotherapy.

Kathy's daughter Chanta Joyner has set up a GoFundMe to fund medical expenses and monthly bills for the family.

Chanta wrote: 'As the news is only just sinking in we are already facing the harsh reality of what this means for my mother - not only the physical and medical challenges but also the many financial ones.

Legendary house music singer Kathy Brown has been diagnosed with stage four lung cancer - with the disease spreading to her brain

'Like most artists who have devoted their careers to dance music, without being able to perform LIVE there's little to no chance of earning an income. My mother has poured her heart and soul onto stages and dance floors all over the world for more than thirty years, and now she needs your love and support more than ever.

'My siblings and I are going to do everything we can to take care of her, but the costs we are facing with medical expenses and monthly bills is overwhelming.

'My mom deserves the best care and comfort that money can buy. I know that she has thousands of fans all over the world who adore her voice and her beautiful spirit.

'Please consider contributing to assist Kathy and get her through the weeks and months ahead. The London-based record label 'Revival' that she has recently been working with have offered to match contributions up to $10,000.

'Let's show my mom that the dance music community really is an extended family who keep each other lifted not only in the good times, but the hard times too. Thank you for the love, support and many messages that you have been posting and sending to Kathy. I promise you that she sees every single one, and they mean so very much to her.

It has already raised nearly $25,000.

To further aid the fundraising effort, Toolroom have also announced a charity single from Wh0, Mark Knight & James Hurr featuring Kathy's iconic vocals, Turn Me Deeper, which be released on January 19.

Brown originally found fame as the chart-topping lead singer of the group Praxis before having US dance hits on her own.

In 1999 she climbed to #4 on the Hot Dance Music/Club Play chart with Joy and in 2004 was the credited lead vocalist on the British act Soul Central's Strings Of Life (Stronger On My Own), a track that samples Rhythm Is Rhythm's 1989 House classic.

Over the years she featured on dozens of house and club singles.

Lung cancer is the leading cause of cancer deaths in the US. It is detected using a low-dose computed tomography scan (CT scan).

One in six people will be diagnosed with lung cancer in their lifetime, and more than 127,000 lives are lost annually.

A recent report by the ACS found that young women are suffering higher rates of lung cancer than men.

Men were nearly twice as likely as women to develop the disease in the 1980s, driven by higher smoking rates and workplace exposure to substances like asbestos.

But with declining cigarette use and safety regulations, the pattern has flipped, with young and middle-aged women now being diagnosed with the disease at higher rates than men.

There were around 65 new cases of lung cancer for every 100,000 people in 1992 and by 2019 this had come down to about 42.

Despite the progress, a disparity among sexes is emerging, with women between the ages of 35 and 54 being diagnosed with lung cancer at higher rates than men in that same age group.

Cigarette smoking remains the leading cause of lung cancer, and while there have been huge drops in overall smoking rates, women have been slower to quit.

By sex, about 67,000 men die from lung cancer every year compared to 59,910 women.

WHAT IS LUNG CANCER?

Lung cancer is one of the most common and serious types of cancer.

Around 47,000 people are diagnosed with the condition every year in the UK.

There are usually no signs or symptoms in the early stages of lung cancer, but many people with the condition eventually develop symptoms including:

- a persistent cough

- coughing up blood

- persistent breathlessness

- unexplained tiredness and weight loss

- an ache or pain when breathing or coughing

You should see a GP if you have these symptoms.

Types of lung cancer

There are two main forms of primary lung cancer.

These are classified by the type of cells in which the cancer starts growing.

They are:

- Non-small-cell lung cancer. The most common form, accounting for more than 87 per cent of cases.

- It can be one of three types: squamous cell carcinoma, adenocarcinoma or large-cell carcinoma.

- Small-cell lung cancer – a less common form that usually spreads faster than non-small-cell lung cancer.

- The type of lung cancer you have determines which treatments are recommended.

Who's affected

Lung cancer mainly affects older people. It's rare in people younger than 40.

More than four out of 10 people diagnosed with lung cancer in the UK are aged 75 and older.

Although people who have never smoked can develop lung cancer, smoking is the most common cause (accounting for about 72 per cent of cases).

This is because smoking involves regularly inhaling a number of different toxic substances.

Treating lung cancer

Treatment depends on the type of mutation the cancer has, how far it's spread and how good your general health is.

If the condition is diagnosed early and the cancerous cells are confined to a small area, surgery to remove the affected area of lung may be recommended.

If surgery is unsuitable due to your general health, radiotherapy to destroy the cancerous cells may be recommended instead.

If the cancer has spread too far for surgery or radiotherapy to be effective, chemotherapy is usually used.

There are also a number of medicines known as targeted therapies.

They target a specific change in or around the cancer cells that is helping them to grow.

Targeted therapies cannot cure lung cancer but they can slow its spread.

Source: NHS

Search This Blog

Lung Cancer